U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C11H14ClN3O3S
Molecular Weight 303.765
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLYCLOPYRAMIDE

SMILES

ClC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCC2

InChI

InChIKey=HNSCCNJWTJUGNQ-UHFFFAOYSA-N
InChI=1S/C11H14ClN3O3S/c12-9-3-5-10(6-4-9)19(17,18)14-11(16)13-15-7-1-2-8-15/h3-6H,1-2,7-8H2,(H2,13,14,16)

HIDE SMILES / InChI
Molecular Formula C11H14ClN3O3S
Molecular Weight 303.765
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Glyclopyramide (N-p-chlorobenzene sul-fonyl, N'-pyrrolidinourea) marketed under the tradename Deamelin-S is a sulfonylurea drug used in the treatment of diabetes mellitus. It has been marketed in Japan.

Originator

Kyorin Pharmaceutical
22

Approval Year

Unknown
149,124

Conditions

ConditionModalityTargetsHighest PhaseProduct
Type 2 diabetes mellitus
262
 Primary
Approved
8,583
DEAMELIN®·S

Cmax

ValueDoseCo-administeredAnalytePopulation
0.37 μg/L
50 μg/kg single, oral
 GLYCLOPYRAMIDE plasma
Homo sapiens
0.76 μg/L
4 mg single, oral
 GLYCLOPYRAMIDE plasma
Homo sapiens
3.47 μg/L
8 μg/kg single, intramuscular
 GLYCLOPYRAMIDE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
276.3 μg × min/L
5 μg/kg single, intravenous
 GLYCLOPYRAMIDE plasma
Homo sapiens
106.6 μg × min/L
50 μg/kg single, oral
 GLYCLOPYRAMIDE plasma
Homo sapiens
8.64 μg × h/L
6 μg/kg single, intravenous
 GLYCLOPYRAMIDE plasma
Homo sapiens
5.2 μg × h/L
4 mg single, oral
 GLYCLOPYRAMIDE plasma
Homo sapiens
5.2 μg × h/L
8 μg/kg single, intramuscular
 GLYCLOPYRAMIDE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
139 min
5 μg/kg single, intravenous
 GLYCLOPYRAMIDE plasma
Homo sapiens
0.83 h
6 μg/kg single, intravenous
 GLYCLOPYRAMIDE plasma
Homo sapiens

Doses

AEs

PubMed

Patents

EP0705607
1

Sample Use Guides

In Vivo Use Guide
oral use is 125 to 250 mg daily, and as required, may be increased to determine a maintenance dose, with the upper limit of 500 mg daily
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
KE474IKG1W
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966